FDA approves costly version of drug for rare disease

The FDA approved Raptor Pharmaceutical's Procysbi to treat nephropathic cystinosis, a rare, inherited pediatric disease. The drug was developed with financing from a foundation started by a patient's parents and is a more easily tolerated version of an existing drug, but Raptor set the price at $250,000.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA